Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. - Wikidata - awgldk - TriplyDB

Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia.

Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q37387647

about

Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia.Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China.Management of chronic lymphocytic leukemia.Obinutuzumab-induced serum sickness following salvage therapy for chronic lymphocytic leukemia.Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia.Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.The spectrum of use of rituximab in chronic lymphocytic leukemia Role of rituximab in first-line treatment of chronic lymphocytic leukemia.Choosing first-line therapy for chronic lymphocytic leukemia.Methylprednisolone suppresses the Wnt signaling pathway in chronic lymphocytic leukemia cell line MEC-1 regulated by LEF-1 expression Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia.Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak.Therapeutic advancement of chronic lymphocytic leukemia.Hearing Loss due to Infiltration of the Tympanic Membrane by Chronic Lymphocytic Leukemia.Treatment options for high-risk chronic lymphocytic leukaemia.Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes.Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia.Frequency and trends of disease-modifying antirheumatic drug (DMARD) use in Germany.Targeted therapy in chronic lymphocytic leukemia: past, present, and future.Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.What is the best frontline therapy for patients with CLL and 17p deletion?Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly.Chronic lymphocytic leukemia in less fit patients: "slow-go".Front-line therapy for chronic lymphocytic leukemia.Treatment of relapsed or refractory chronic lymphocytic leukemia.Rituximab for chronic lymphocytic leukemia.Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis.Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.Emerging therapies for refractory chronic lymphocytic leukemia.An update on current and prospective immunotherapies for chronic lymphocytic leukemia.What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?Rituximab for the treatment of patients with chronic lymphocytic leukemia Chronic lymphocytic leukemia associated with immunotactoid glomerulopathy: a case report of successful treatment with high-dose methylprednisolone in combination with rituximab followed by alemtuzumab.

P2860

Q24203027-FAB8FEE7-B650-4DCD-97CE-CA21E5E761A2 Q27024411-734634D4-49C2-4AEE-A5DD-99596B1F5267 Q30417730-368F66C9-43E0-4986-A2AF-FF5F7F621551 Q33649977-F8252913-9F98-446D-B2D3-003AA5207945 Q33695912-C8E0CC2A-4560-4197-A87C-903B56F5E8B2 Q33760975-84C69311-B387-4DB6-8E9E-F750A479B604 Q33965688-3FE002C3-A939-45B8-B2BC-7641285907CA Q33978930-05DCDA76-3A71-403F-BB70-F67EB2CB3A85 Q34510030-1F647290-B8EB-4855-B390-E5C953F312B4 Q34574147-995FDC99-8CDE-4419-9E66-6D04176E4AA1 Q35124844-729CDA4D-BFC0-4884-B47A-01ED6FE152C1 Q36014206-08379195-7FCC-407F-AEED-DCF4ECC2305D Q36065294-03D8B5A1-06F2-42BA-B0F4-5252DBB54B31 Q36211482-B3CD8365-8B4C-4285-B012-DDECE5838921 Q36300303-D72B36C7-9D32-4853-93B3-AEE03420A901 Q36413427-73E58A3F-52BE-43C3-94D1-9CECF8089CC3 Q36612587-EA380BBE-2394-450A-B058-071965989F77 Q36628641-C57CE67B-5721-4403-86C8-FF0B0B015FDD Q36845282-4B00D7D2-1341-4C16-B187-BE598DD881B5 Q37303008-67EBCFE7-50C4-42C9-B1EB-64FA6A370E11 Q37430243-A3461B63-7065-449F-99D7-AE68FF30697E Q37799820-1510D8CB-6FBD-499D-B7CC-E5D787447DBF Q37820433-7D461135-73ED-4333-9C78-DE7DDEB60570 Q37844139-57B14EA8-9BFE-4E0D-BB6C-6992C2A76CBE Q37903038-2E3E0884-F777-4FB1-B5A6-00FE52171744 Q37964914-9669CFC5-76DD-4D37-8314-9CF9AD4A20D7 Q37964916-0C9028A6-E865-4214-BAAA-CD67A79A0BAC Q37988562-9A576AD6-41E3-4BC5-A6ED-D83333565B8E Q38007853-4DAAC8DD-9A39-4AAF-A3EB-6BB9902DC678 Q38068932-6C3B9B33-847B-44B5-B992-86A556ADE094 Q38155343-068C2C56-8379-41E6-9DC2-7B99990272A7 Q38207143-0452EA00-1E61-416A-A56E-67689BD47DA2 Q38445357-1593A77A-2B4B-4B68-A426-56BAA54DEC15 Q39154057-0FD8A574-9B00-4EE7-A3B0-31302E65648A Q41241909-40DE7625-3890-445A-BB24-6A687E4F3666 Q43055766-83D18050-260D-4538-958E-A7F1C2330D7D

P2860

Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q37387647

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Rituximab in combination with ...... chronic lymphocytic leukemia.

@en

Rituximab in combination with ...... chronic lymphocytic leukemia.

@nl

type

label

Rituximab in combination with ...... chronic lymphocytic leukemia.

@en

Rituximab in combination with ...... chronic lymphocytic leukemia.

@nl

prefLabel

Rituximab in combination with ...... chronic lymphocytic leukemia.

@en

Rituximab in combination with ...... chronic lymphocytic leukemia.

@nl

P1433

Q37387647-A7A23B0D-90F3-4511-94E0-1B09F53D46A2

P1476

Q37387647-BB0B0456-734B-4525-94C9-66E337BC7A7A

P2093

Q37387647-0D2FD985-0AFB-49AC-BB2B-40C977BCEFEF

Q37387647-245B6E2F-323F-438D-B776-76BAE8C68F45

Q37387647-8310ABE0-5CCE-4C5B-A45E-41DE96B17F4F

Q37387647-8C31CC85-C518-4420-BDAD-27440BB750E3

Q37387647-981DD6BA-596C-4780-8B92-15E45F40D541

Q37387647-A1EE72E8-FE4B-4F31-AF8E-AACEC3716D12

Q37387647-BAE266FA-37AF-4F13-99CE-BF87B3B84E2F

P2860

Q37387647-02E3336E-3C1A-45B7-8101-297E5B72DEF3

Q37387647-09431924-7074-4CA5-92FA-05759DB50445

Q37387647-215EFDE3-CA20-4F37-AD51-E43B115BD08D

Q37387647-24A130AB-3E99-485D-9951-EEADB42DDC71

Q37387647-316436DF-1748-4CB3-89C8-398698EEC264

Q37387647-3BF555E6-A08C-4BC1-81F1-BB1A348F12A6

Q37387647-3FCDE7FE-4662-4B3E-B960-51F91CD76B50

Q37387647-4F8C6724-E4F2-4549-816A-091FF0F5F955

Q37387647-4FBE460D-0C25-47AD-BC5C-1CAB81DD08E6

Q37387647-5A100A8A-5270-4213-95F0-C6926862D71B

P2888

Q37387647-E610A8D4-B6D1-4403-9A95-651279428212

P304

Q37387647-015ABE53-4134-4BD6-B9C7-79AE0681C9C8

P31

Q37387647-C0205965-03B9-4A1D-861A-641B1B627C2C

P356

Q37387647-7328BF0E-6565-4657-BC86-46F30B666DF4

P433

Q37387647-A37EC4FF-C364-4EF2-A69A-059C5C897FEF

P478

Q37387647-DA4D260E-D0D6-43A7-B9FF-ED7D1CCF6012

P577

Q37387647-475BB9AB-1113-4339-A1C8-DD26075154EF

P698

Q37387647-CA3F8E49-1C6B-4533-9773-C49E3B04F2B6

P921

Q37387647-A1562CAC-FA3B-499C-BA97-1E48DF5B5FBF

Q37387647-B4FA5DD8-2EFD-425D-BA79-41CDEB3F750A

P932

Q37387647-8FC9000C-3E60-491F-B9AB-4F16189AFBF8

P356

P1433

P1476

Rituximab in combination with ...... chronic lymphocytic leukemia.

@en

P2093

D F James

http://www.w3.org/2001/XMLSchema#string

J Bole

http://www.w3.org/2001/XMLSchema#string

J D Sandoval-Sus

http://www.w3.org/2001/XMLSchema#string

J E Castro

http://www.w3.org/2001/XMLSchema#string

L Rassenti

http://www.w3.org/2001/XMLSchema#string

S Jain

http://www.w3.org/2001/XMLSchema#string

T J Kipps

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

Genomic aberrations and survival in chronic lymphocytic leukemia

Chronic lymphocytic leukemia

The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia.

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

P2888

P304

1779-1789

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2009.133

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19693094

http://www.w3.org/2001/XMLSchema#string

P921

P932

2761991

http://www.w3.org/2001/XMLSchema#string